The Technical Analyst
MeiraGTx Holdings PLC [MGTX]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
MeiraGTx Holdings PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.47% $7.71
America/New_York / 6 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 458.75 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Aug 09, 2023 |
| SharesOutstanding: | 59.50 mill |
| Avg Daily Volume: | 0.143 mill |
| RATING 2023-06-06 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.38x |
| Company: PE 0 | industry: PE 6.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$10.27 (33.16%) $2.56 |
| Date: 2023-06-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.24 - 8.18 ( +/- 6.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-05 | Perceptive Advisors Llc | Buy | 4 347 826 | Ordinary Shares |
| 2023-02-21 | Zeldin Robert K | Buy | 30 000 | Stock Option (Right to Buy) |
| 2023-02-21 | Zeldin Robert K | Buy | 30 000 | Restricted Share Units |
| 2023-02-21 | Wollin Robert J | Buy | 45 000 | Stock Option (Right to Buy) |
| 2023-02-21 | Wollin Robert J | Buy | 45 000 | Restricted Share Units |
| INSIDER POWER |
|---|
| 78.43 |
| Last 94 transactions |
| Buy: 7 410 082 | Sell: 1 042 424 |
Forecast:
16:00 - $7.71
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.71
Forecast 2: 16:00 - $7.71
Forecast 3: 16:00 - $7.71
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.71 (4.47% ) |
| Volume | 0.106 mill |
| Avg. Vol. | 0.143 mill |
| % of Avg. Vol | 74.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MGTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2023-05-11 08:00:00 - Press Release
Meiragtx Reports First Quarter 2023 Financial And Operational Results
London and new york, may 11, 2023 (globe newswire) -- meiragtx holdings plc (nasdaq: mgtx), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended march 31, 2023, and provided a corporate update.
2023-05-03 08:30:00 - Press Release
Meiragtx Announces $60 Million Private Placement Of Ordinary Shares
London and new york, may 03, 2023 (globe newswire) -- meiragtx holdings plc (nasdaq: mgtx), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. meiragtx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. the company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general corporate purposes.
2023-04-21 08:30:00 - Press Release
Meiragtx Announces Upcoming Presentations At The Association For Research In Vision And Ophthalmology (arvo) 2023 Annual Meeting
London and new york, april 21, 2023 (globe newswire) -- meiragtx holdings plc (nasdaq: mgtx), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the association for research in vision and ophthalmology (arvo) 2023 annual meeting.
2023-03-14 08:00:00 - Press Release
Meiragtx Reports Fourth Quarter And Full Year 2022 Financial And Operational Results
- announced positive clinical data from aquax aav-haqp1 phase 1 trial for treatment of grade 2/3 radiation-induced xerostomia in december 2022
2022-10-04 08:00:00 - Press Release
Meiragtx Announces The Upcoming Presentation Of 15 Abstracts At The European Society Of Gene And Cell Therapy (esgct) 2022 Annual Congress
Multiple poster presentations highlight versatility and novelty of meiragtx's technology platforms for gene and cell therapy multiple poster presentations highlight versatility and novelty of meiragtx's technology platforms for gene and cell therapy
Latest News
2023-06-02 11:09:30 - Zacks Investment Research
Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect?
The consensus price target hints at a 320.9% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-04-20 17:00:00 - GlobeNewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
2022-12-08 16:30:00 - GlobeNewsWire
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company's AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 13, 2022, at 8:00 a.m. ET.
2022-11-22 16:30:00 - GlobeNewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
2022-09-08 16:30:00 - GlobeNewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
2022-08-11 11:18:33 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-12 10:32:12 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-30 08:17:06 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2022-03-10 10:32:08 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-12-16 15:49:00 - Barrons
A Biotech Unveils Its New Gene Control Technology
MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.